Screening for adverse reactions to irinotecan treatment using the Invader® UGT1A1 Molecular Assay

Expert Review of Molecular Diagnostics

Volumn 6, Issue 4, 2006, Pages 527-533

  Hasegawa, Yoshinori ^a   Ando, Yuichi ^b   Shimokata, Kaoru ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Invader assay; Irinotecan; Polymorphism; UDP glucuronosyltransferase; UGT1A1*27; UGT1A1*28; UGT1A1*6

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN;

ALLELE; DIAGNOSTIC PROCEDURE; DNA POLYMORPHISM; DRUG DOSE REDUCTION; ENZYME ASSAY; GENOTYPE; HOMOZYGOSITY; HUMAN; MOLECULAR BIOLOGY; NEUTROPENIA; PHARMACOGENETICS; PROTEIN POLYMORPHISM; REVIEW; SCREENING; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR;

ALLELES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL ASSAY; CAMPTOTHECIN; GENE FREQUENCY; GENOTYPE; GLUCURONOSYLTRANSFERASE; HOMOZYGOTE; HUMANS; MODELS, GENETIC; NEOPLASMS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); TECHNOLOGY, PHARMACEUTICAL;

EID: 33746806883     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.6.4.527     Document Type: Review

References (44)

1. Gong QH, Cho JW, Huang T et al. Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11, 357-368 (2001).
2. Bock KW. Vertebrate UDP-glucuronosyltransferases: functional and evolutionary aspects. Biochem. Pharmacol. 66, 691-396 (2003).
3. Bosma PJ, Chowdhury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333, 1171-1175 (1995).
4. Seppen J, Bosma PJ, Goldhoorn BG et al. Discrimination between Crigler-Najjar Type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J. Clin. Invest. 94, 2385-2391 (1994).
5. Ando Y, Chida M, Nakayama K et al. The UGT1A1*28 allele is relatively rare in a Japanese population. Pharmacogenetics 8, 357-360 (1998).
6. Ando Y, Saka H, Ando M et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921-6926 (2000). • First retrospective case-control study that demonstrated an important role of UGT1A1*28 allele associated with the development of toxicity after irinotecan chemotherapy.
7. Ando Y, Ueoka H, Sugiyama T et al. Polymorphisms of UDP- glucuronosyltransferase and pharmacokinetics of irinotecan. Ther. Drug Monit. 24, 111-116 (2002).
8. Innocenti F, Grimsley C, Das S et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12, 725-733 (2002).
9. Iyer L, Das S, Janisch L et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2, 43-47 (2002). • First prospective pharmacogenetic investigation of the influence of the UGT1A1*28 polymorphism on the disposition and toxicity of irinotecan.
10. Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22, 1382-1388 (2004). • Prospective study that evaluated the association between the prevalence of severe toxicity and UGT1A1 polymorphism.
11. Marcuello E, Altes A, Menoyo A et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91, 678-682 (2004).
12. Paoluzzi L, Singh AS, Price DK et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J. Clin. Pharmacol. 44, 854-860 (2004).
13. Kitagawa C, Ando M, Ando Y et al. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenet. Genomics 15, 35-41 (2005).
14. Ando Y, Hasegawa Y. Clinical pharmacogenetics of irinotecan (CPT-11). Drug Metab. Rev. 37, 565-574 (2005).
15. Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346, 85-91 (2002).
16. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343, 905-914 (2000).
17. Tadokoro J, Hasegawa H, Hayakawa K et al. Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients. Proc. Am. Soc. Clin. Oncol. 21(Suppl.), 259a (2002) (Abstract 1033).
18. Iyer L, King CD, Whitington PF et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 101, 847-854 (1998).
19. Iyer L, Hall D, Das S et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther. 65, 576-582 (1999).
20. Senafi SB, Clarke DJ, Burchell B. Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem. J. 303(Pt 1), 233-240 (1994).
21. Ritter JK, Chen F, Sheen YY et al. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J. Biol. Chem. 267, 3257-3261 (1992).
22. Mackenzie PI, Owens IS, Burchell B et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7, 255-269 (1997).
23. Monaghan G, Ryan M, Seddon R et al. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347, 578-581 (1996).
24. Yamamoto K, Soeda Y, Kamisako T et al. Analysis of bilirubin uridine 5′-diphosphate (UDP)-glucuronosyltransferase gene mutations in seven patients with Crigler-Najjar syndrome Type II. J. Hum. Genet. 43, 111-114 (1998).
25. McLeod HL, Watters JW. Irinotecan pharmacogenetics: is it time to intervene? J. Clin. Oncol. 22, 1356-1359 (2004).
26. Akaba K, Kimura T, Sasaki A et al. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem. Mol. Biol. Int. 46, 21-26 (1998).
27. Beutler E, Gelbart T, Demina A. Racial variability in the UDPglucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sci. USA 95, 8170-8174 (1998).
28. Sai K, Saeki M, Saito Y et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 75, 501-515 (2004).
29. Akaba K, Kimura T, Sasaki A et al. Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese. J. Hum. Genet. 44, 22-25 (1999).
30. Maruo Y, Nishizawa K, Sato H et al. Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism. Pediatrics 103, 1224-1227 (1999).
31. Yamamoto K, Sato H, Fujiyama Y et al. Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome Type II. Biochim. Biophys. Acta 1406, 267-273 (1998).
32. Sato H, Adachi Y, Koiwai O. The genetic basis of Gilbert's syndrome. Lancet 347, 557-558 (1996).
33. Han JY, Lim HS, Shin ES et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24, 2237-2244 (2006).
34. Hasegawa Y, Sarashina T, Ando M et al. Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay. Clin. Chem. 50, 1479-1480 (2004). • First report on the development of the Invader® UGT1A1 Molecular Assay, and the evaluation with clinical samples.
35. Lyamichev V, Mast AL, Hall JG et al. Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat. Biotechnol. 17, 292-296 (1999).
36. Ghosh SS, Eis PS, Blumeyer K et al. Real time kinetics of restriction endonuclease cleavage monitored by fluorescence resonance energy transfer. Nucleic Acids Res. 22, 3155-3159 (1994).
37. Patnaik M, Dlott JS, Fontaine RN et al. Detection of genomic polymorphisms associated with venous thrombosis using the invader biplex assay. J. Mol. Diagn. 6, 137-144 (2004).
38. Neville M, Selzer R, Aisenstein B et al. Characterization of cytochrome P450 2D6 alleles using the Invader System. Biotechniques 32, S34-S43 (2002).
39. Kitagawa C, Ando M, Ando Y et al. Genetic polymorphisms of the multidrug resistance-associated protein 2 gene (ABCC2) and irinotecan toxicity. Proc. Am. Soc. Clin. Oncol. 22(Suppl.), 129 (2004) (Abstract 2009).
40. Innocenti F, Undevia SD, Chen PX et al. Pharmacogenetic analysis of interindividual irinotecan (CPT-11) pharmacokinetic (PK) variability: evidence for a functional variant of ABCC2. Proc. Am. Soc. Clin. Oncol. 22(Suppl.), 129 (2004) (Abstract 2010).
41. Human UGT Allele Tables http://som.flinders.edu.au/FUSA/ClinPharm/UGT/ allele_table.html
42. Camptosar®: irinotecan hydrochloride injection www.fda.gov/medwatch/ SAFETY/2005/Jun_PI/Camptosar_PI.pdf
43. DNA sequence data of Invader probes www.clinchem.org/cgi/content/full/50/ 8/1479/DC1
44. 510(k) Premarket Notification Database www.accessdata.fda.gov/scripts/ cdrh/cfdocs/search/search.cfm?db=PMN&ID=K051824